化合物TAK-593 T16975

Product Introduction
Bioactivity


英文名: TAK-593

描述: TAK-593 是一种 VEGFR2 和 PDGFR 抑制剂，能够作用于VEGFR1 (IC50:3.2 nM)、VEGFR2 (IC50:0.95 nM)、VEGFR3 (IC50:1.1 nM)、PDFGRα (IC50:4.3 nM)、PDFGRβ (IC50:13 nM)。

体外活性: TAK-593 inhibits the growth of HUVEC (IC50: 0.30 nM). TAK-593 also potently inhibits VEGF-induced tube formation of endothelial cells co-cultured with fibroblasts. TAK-593 potently inhibits VEGF- and PDGF-stimulated cellular phosphorylation and proliferation of human umbilical vein endothelial cells and human coronary artery smooth muscle cells. It displays effective inhibitory activity against VEGFR (VEGFR1-3: IC50=3.2, 0.95, 1.1 nM) and PDGFR (PDGFRα, β: IC50=4.3, 13 nM) families. Against other kinases, the IC50 values of TAK-593 are above 100 nM, except for Fms (IC50=10 nM) and Ret (IC50=18 nM) kinases [1][2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 45 mg/mL (101.02 mM)


关键字: TAK 593 | Platelet-derived growth factor receptor | VEGFR | PDGFR | Inhibitor | TAK593 | inhibit | TAK-593 | Vascular endothelial growth factor receptor

相关产品: FGFR1/VEGFR2-IN-1 | Icrucumab | AAL-993 | Toceranib Phosphate | Royal Jelly acid | CYC-116 | N-Desethyl Sunitinib | WHI-P154 | SKLB 610 | Ranibizumab

相关库: Drug Repurposing Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Orally Active Compound Library

化合物TAK-593 T16975信息由TargetMol中国为您提供，如您想了解更多关于化合物TAK-593 T16975报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途